TriangleHEALTH PROFESSIONAL · SOURCE READING
Treatment Options Under Clinical Evaluation for Primary CNS Tumors
Source: Central Nervous System Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 28, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Treatment of Primary CNS Tumors by Tumor Type
Patients who have central nervous system (CNS) tumors that are either infrequently curable or unresectable should consider enrollment in clinical trials. Information about ongoing clinical trials is available from the NCI website.
Source links and citations
Heavy-particle radiation, such as proton-beam therapy, carries the theoretical advantage of delivering high doses of ionizing radiation to the tumor bed while sparing surrounding brain tissue. The data are preliminary for this investigational technique and are not widely available.
Novel biological therapies under clinical evaluation for patients with CNS tumors include:[36]
Source links and citations
Dendritic cell vaccination.[37]
Source links and citations
Tyrosine kinase receptor inhibitors.[38]
Source links and citations
Farnesyl transferase inhibitors.
Oncolytic viruses.
Epidermal growth factor-receptor inhibitors.
Vascular endothelial growth factor inhibitors.[36]
Source links and citations
Other antiangiogenesis agents.
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice